litlas
Log inCreate account

Michael C. Heinrich

Active 1997–2025

167
Papers
47,228
Citations
102
h-index
163
i10-index

Citations

Citations per year for Michael C. Heinrich1992: 2 citations1996: 3 citations1998: 12 citations1999: 6 citations2000: 11 citations2001: 36 citations2002: 61 citations2003: 240 citations2004: 318 citations2005: 448 citations2006: 481 citations2007: 490 citations2008: 551 citations2009: 643 citations2010: 513 citations2011: 462 citations2012: 473 citations2013: 403 citations2014: 352 citations2015: 296 citations2016: 238 citations2017: 311 citations2018: 227 citations2019: 882 citations2020: 878 citations2021: 1,036 citations2022: 759 citations2023: 492 citations2024: 795 citations2025: 227 citations2026: 5 citations1993–1995: no citations, so these years are not shown1997: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,072 citing papers, 31.8% of this breakdownGermany: 635 citing papers, 6.6% of this breakdownChina: 622 citing papers, 6.4% of this breakdownItaly: 552 citing papers, 5.7% of this breakdownUnited Kingdom: 535 citing papers, 5.5% of this breakdownFrance: 517 citing papers, 5.4% of this breakdownNetherlands: 315 citing papers, 3.3% of this breakdownJapan: 303 citing papers, 3.1% of this breakdownCanada: 265 citing papers, 2.7% of this breakdownAustralia: 258 citing papers, 2.7% of this breakdownSwitzerland: 258 citing papers, 2.7% of this breakdownSpain: 256 citing papers, 2.7% of this breakdown
0%31.8%Other 21.4%

Institutions

Fields

  • Medicine70.8%
  • Biochemistry, Genetics and Molecular Biology21.2%
  • Immunology and Microbiology3.8%
  • Computer Science1%
  • Chemistry0.7%
  • Neuroscience0.7%
  • Other1.8%

Topics

  • Gastrointestinal Tumor Research and Treatment6.4%
  • Chronic Myeloid Leukemia Treatments5.9%
  • Sarcoma Diagnosis and Treatment4.2%
  • Chronic Lymphocytic Leukemia Research2.9%
  • Acute Myeloid Leukemia Research2.7%
  • Gastrointestinal disorders and treatments2.5%
  • Other75.4%

Coauthors

All papers

Open in search
  1. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

    Authors: Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, Hironobu Minami, Delphine Réa, Daniel J. DeAngelo, Massimo Breccia, Yeow-Tee Goh, Moshe Talpaz, Andreas Hochhaus, Philipp le Coutre, Oliver G. Ottmann, Michael C. Heinrich, Juan Luis Steegmann, Michael W. Deininger, Jeroen J. W. M. Janssen, François-Xavier Mahon, Yosuke Minami, David T Yeung, David M. Ross, Martin S. Tallman, Jae H. Park, Brian Druker, David Hynds, Yuyan Duan, Christophe Meille, Florence Hourcade‐Potelleret, K. Gary J. Vanasse, Fabian Lang, Dong‐Wook Kim - New England Journal of Medicine 2019 cited by 467

  2. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

    Authors: George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter Roberts‎, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos J. Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Saša Dimitrijević, Brian Druker, Christopher L. Corless, Christopher D.�M. Fletcher, Heikki Joensuu - New England Journal of Medicine 2002 cited by 4,389

  3. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    Authors: George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett, Martin E. Blackstein, Manisha H. Shah, Jaap Verweij, Grant A. McArthur, Ian Judson, Michael C. Heinrich, Jeffrey A. Morgan, Jayesh Desai, Christopher D.�M. Fletcher, Suzanne George, Carlo L. Bello, Xin Huang, Charles M. Baum, Paolo G. Casali - The Lancet 2006 cited by 2,595

  4. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

    Authors: Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage, Orlando Antelope, Nadeem A. Vellore, Hein Than, Anna Reister Schultz, Phillip M. Clair, Amber D. Bowler, Anthony D. Pomicter, Dongqing Yan, Anna V. Senina, Qiang Wang, Todd W. Kelley, Philippe Szankasi, Michael C. Heinrich, Jeffrey Tyner, Delphine Réa, Jean-Michel Cayuela, Dong‐Wook Kim, Cristina E. Tognon, Thomas O’Hare, Brian Druker, Michael W. Deininger - Cancer Cell 2019 cited by 245

  5. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

    Authors: Michael C. Heinrich, Christopher L. Corless, Anette Duensing, Laura McGreevey, Chang-Jie Chen, Nora Joseph, Samuel Singer, Diana Griffith, Andrea Haley, Ajia Town, George D. Demetri, Christopher D.�M. Fletcher, Jonathan A. Fletcher - Science 2003 cited by 2,302

  6. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

    Authors: Michael C. Heinrich, Robin L. Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon‐Koo Kang, Philippe A. Cassier, Olivier Mir, Ferry A.L.M. Eskens, William D. Tap, Piotr Rutkowski, Sant P. Chawla, Jonathan C. Trent, Meera Tugnait, Erica N Evans, Tamieka Lauz, Teresa Zhou, Maria Roche, Beni B. Wolf, Sebastian Bauer, Suzanne George - The Lancet Oncology 2020 cited by 304

  7. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Jean‐Yves Blay, César Serrano, Michael C. Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Meade, Kelvin Shi, Rodrigo Ruiz‐Soto, Suzanne George, Margaret von Mehren - The Lancet Oncology 2020 cited by 407

  8. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

    Authors: Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu, Anu Gupta, Cynthia B. Leary, Scott Wise, Thomas J. Rutkoski, Yu Mi Ahn, Gada Al-Ani, Stacie L. Bulfer, Timothy M. Caldwell, Lawrence Chun, Carol L. Ensinger, Molly M. Hood, Arin McKinley, William C. Patt, Rodrigo Ruiz‐Soto, Ying Su, Hanumaiah Telikepalli, Ajia Town, Benjamin A. Turner, Lakshminarayana Vogeti, Subha Vogeti, Karen Yates, Filip Jankú, Albiruni Ryan Abdul Razak, Oliver Rosen, Michael C. Heinrich, Daniel L. Flynn - Cancer Cell 2019 cited by 277

  9. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

    Authors: F. Stephen Hodi, Christopher L. Corless, Anita Giobbie‐Hurder, Jonathan A. Fletcher, Mei‐Jun Zhu, Adrián Mariño‐Enríquez, Philip Friedlander, René González, Jeffrey S. Weber, Thomas F. Gajewski, Steven O’Day, Kevin B. Kim, Donald P. Lawrence, Keith T. Flaherty, Jason J. Luke, Frances A. Collichio, Marc S. Ernstoff, Michael C. Heinrich, Carol Beadling, Katherine Zukotynski, Jeffrey T. Yap, Annick D. Van den Abbeele, George D. Demetri, David E. Fisher - Journal of Clinical Oncology 2013 cited by 595

  10. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Authors: Michael C. Heinrich, Christopher L. Corless, George D. Demetri, Charles D. Blanke, Margaret von Mehren, Heikki Joensuu, Laura McGreevey, Changjie Chen, Annick D. Van den Abbeele, Brian Druker, Beate Kiese, Burton Eisenberg, Peter Roberts‎, Samuel Singer, Christopher D.�M. Fletcher, Sandra Silberman, Saša Dimitrijević, Jonathan A. Fletcher - Journal of Clinical Oncology 2003 cited by 2,297

  11. Gastrointestinal stromal tumours: origin and molecular oncology

    Authors: Christopher L. Corless, Christine M. Barnett, Michael C. Heinrich - Nature reviews. Cancer 2011 cited by 887

  12. New treatment strategies for advanced-stage gastrointestinal stromal tumours

    Authors: Lillian R. Klug, Homma M. Khosroyani, Jason D. Kent, Michael C. Heinrich - Nature Reviews Clinical Oncology 2022 cited by 130

  13. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

    Authors: Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich - Journal of Clinical Oncology 2022 cited by 111

  14. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

    Authors: Michael J. Mauro, Timothy P. Hughes, Dong‐Wook Kim, Delphine Réa, Jörge E. Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver G. Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Michael C. Heinrich, Valle Gómez-Garcı́a de Soria, Philipp le Coutre, François‐Xavier Mahon, Jeroen J. W. M. Janssen, Michael W. Deininger, Naranie Shanmuganathan, Mark B. Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang - Leukemia 2023 cited by 47

  15. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

    Authors: César Serrano, Adrián Mariño‐Enríquez, Derrick L. Tao, Julia Ketzer, Grant Eilers, Mei‐Jun Zhu, Channing Yu, Aristotle M. Mannan, Brian P. Rubin, George D. Demetri, Chandrajit P. Raut, Ajia Presnell, Arin McKinley, Michael C. Heinrich, Jeffrey T. Czaplinski, Ewa Sicińska, Sebastian Bauer, Suzanne George, Jonathan A. Fletcher - British Journal of Cancer 2019 cited by 166

  16. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

    Authors: Christopher L. Corless, Arin Schroeder, Diana Griffith, Ajia Town, Laura McGreevey, Patina M. Harrell, Sharon Shiraga, Troy Bainbridge, Jason R. Morich, Michael C. Heinrich - Journal of Clinical Oncology 2005 cited by 838

  17. The contemporary management of cancers of the sinonasal tract in adults

    Authors: Rajat Thawani, Myung Sun Kim, Asad Arastu, Zizhen Feng, Malinda West, Nicholas Taflin, Kyaw Zin Thein, Ryan Li, Mathew Geltzeiler, Nancy Y. Lee, Clifton D. Fuller, Jennifer R. Grandis, Charalampos S. Floudas, Michael C. Heinrich, Ehab Hanna, Ravi A. Chandra - CA A Cancer Journal for Clinicians 2022 cited by 118

  18. Heterogeneity of kinase inhibitor resistance mechanisms in GIST

    Authors: Bernadette Liegl, Ilana Kepten, Claudia Le, Mei‐Jun Zhu, George D. Demetri, Michael C. Heinrich, CDM Fletcher, Christopher L. Corless, JA Fletcher - The Journal of Pathology 2008 cited by 455

  19. FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

    Authors: Eileen Shi, Juliann Chmielecki, Chih‐Min Tang, Kai Wang, Michael C. Heinrich, Guhyun Kang, Christopher L. Corless, David S. Hong, Katherine E. Fero, James D. Murphy, Paul T. Fanta, Siraj M. Ali, Martina De Siena, Adam M. Burgoyne, Sujana Movva, Lisa Madlensky, Gregory M. Heestand, Jonathan C. Trent, Razelle Kurzrock, Deborah Morosini, Jeffrey S. Ross, Olivier Harismendy, Jason K. Sicklick - Journal of Translational Medicine 2016 cited by 233

  20. Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis

    Authors: Hyunho Yoon, Chih-Min Tang, Sudeep Banerjee, Mayra Yebra, Sangkyu Noh, Adam M. Burgoyne, Jorge de la Torre, Martina De Siena, Mengyuan Liu, Lillian R. Klug, Yoon Young Choi, Mojgan Hosseini, Antonio L. Delgado, Zhiyong Wang, Randall P. French, Andrew M. Lowy, Ronald P. DeMatteo, Michael C. Heinrich, Alfredo Molinolo, J. Silvio Gutkind, Olivier Harismendy, Jason K. Sicklick - Oncogene 2021 cited by 54

  21. Gastrointestinal stromal tumour

    Authors: Brian P. Rubin, Michael C. Heinrich, Christopher L. Corless - The Lancet 2007 cited by 1,043

  22. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

    Authors: Thomas O’Hare, Denise K. Walters, Eric P. Stoffregen, Taiping Jia, Paul W. Manley, Jürgen Mestan, Sandra W. Cowan‐Jacob, Francis Y. Lee, Michael C. Heinrich, Michael W. Deininger, Brian Druker - Cancer Research 2005 cited by 1,034

  23. KIT Gene Mutations and Copy Number in Melanoma Subtypes

    Authors: Carol Beadling, Erick Jacobson‐Dunlop, F. Stephen Hodi, Claudia Le, Andrea Warrick, Janice Patterson, Ajia Town, Amy Harlow, Frank Cruz, Sharl Azar, Brian P. Rubin, Susan Müller, Robert B. West, Michael C. Heinrich, Christopher L. Corless - Clinical Cancer Research 2008 cited by 636

  24. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study

    Authors: Yoon‐Koo Kang, Suzanne George, Robin L. Jones, Piotr Rutkowski, Lin Shen, Olivier Mir, Shreyaskumar Patel, Yongjian Zhou, Margaret von Mehren, Peter Hohenberger, Víctor M. Villalobos, Mehdi Brahmi, William D. Tap, Jonathan C. Trent, Maria A. Pantaleo, Patrick Schöffski, Kevin He, Paggy Hew, Kate J. Newberry, Maria Roche, Michael C. Heinrich, Sebastian Bauer - Journal of Clinical Oncology 2021 cited by 116